Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Increases By 148.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 99,000 shares, a growth of 148.1% from the November 15th total of 39,900 shares. Approximately 1.3% of the company’s shares are sold short. Based on an average trading volume of 90,700 shares, the short-interest ratio is currently 1.1 days.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on SABS shares. Oppenheimer restated an “outperform” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Craig Hallum initiated coverage on SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target for the company. Finally, Chardan Capital reiterated a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SAB Biotherapeutics currently has a consensus rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Price Performance

SABS stock traded down $0.07 during midday trading on Thursday, reaching $3.78. 16,872 shares of the company’s stock traded hands, compared to its average volume of 35,210. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a fifty-two week low of $2.16 and a fifty-two week high of $8.40. The business has a 50-day moving average price of $3.11 and a two-hundred day moving average price of $2.91.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, research analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC acquired a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned 0.21% of SAB Biotherapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.